fda warning letter compounding semaglutide october 2025 Sends Letters to More Than 50 GLP-1 Compounders and Manufacturers FDA Drug Recalls and Warnings:

HSA/FSA accounts are available to reduce costs further

Keep applying pressure until the yellow bar stops moving

New IVIM Study Shows 21.8% Average Weight Loss Over 68 Weeks Exceeding Outcomes Reported in Landmark GLP-1 Trials A new publication reveals breakthrough results in GLP-1 obesity management using Ivim Healths individualized virtual integrative medicine (IVIM) protocol

But outreach is still needed to fully inform both patients as well as providers about the program, says Anders Gilberg, senior vice president of government affairs for the Medical Group Management Association

In this episode we unpack why a non-allergic runny nose happens on GLP-1s, from autonomic nervous system shifts to reflux links and hydration hacks